Woman is truly the future of man!

Eur Ann Otorhinolaryngol Head Neck Dis

European Annals of Otorhinolaryngology Head & Neck Diseases, Elsevier, 165, rue Camille-Desmoulins, 92130 Issy-les-Moulineaux, France; Service d'otorhinolaryngologie et de chirurgie cervico-faciale, HEGP, AP-HP, université Paris Cité, 20, rue Leblanc, 75015 Paris, France. Electronic address:

Published: September 2024

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anorl.2024.06.007DOI Listing

Publication Analysis

Top Keywords

woman future
4
future man!
4
woman
1
man!
1

Similar Publications

The incidence of type 2 diabetes has risen globally, in parallel with the obesity epidemic and environments promoting a sedentary lifestyle and low-quality diet. There has been scrutiny of ultra-processed foods (UPFs) as a driver of type 2 diabetes, underscored by their increasing availability and intake worldwide, across countries of all incomes. This narrative review addresses the accumulated evidence from investigations of the trends in UPF consumption and the relationship with type 2 diabetes incidence.

View Article and Find Full Text PDF

Associations between anthropogenic heat emissions and serum lipids among adults in northeastern China.

Int J Environ Health Res

January 2025

Guangdong Provincial Engineering Technology Research Center of Environmental Pollution and Health Risk Assessment, Department of Occupational and Environmental Health, School of Public Health, Sun Yat-sen University, Guangzhou, China.

Few epidemiological studies have investigated associations between anthropogenic heat emissions (AE) and serum lipids. We recruited 15,477 adults from 33 communities in northeastern China in 2009. We estimated AE flux by using data on energy consumption and socio-economic statistics covering building, transportation, industry, and human metabolism.

View Article and Find Full Text PDF

New onset refractory status epilepticus: Long-term outcomes beyond seizures.

Epilepsia

January 2025

Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

We propose and prioritize important outcome domains that should be considered for future research investigating long-term outcomes (LTO) after new onset refractory status epilepticus (NORSE). The study was led by the international NORSE Institute LTO Working Group. First, literature describing the LTO of NORSE survivors was identified using a PubMed search and summarized to identify knowledge gaps.

View Article and Find Full Text PDF

A surge in female condom distribution during the COVID-19 pandemic in Gauteng province, South Africa.

Contracept Reprod Med

January 2025

School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Background: Female Condoms are 90-95% effective against HIV transmission when correctly and consistently used and are also cost-effective. In general, condoms prevent sexually transmitted infections (STIs) and unwanted pregnancies. Although the COVID-19 pandemic had the potential to undermine routine healthcare services delivery and utilisation, there is limited evidence about the pandemic's effect on Female Condom uptake in Gauteng, one of the hardest-hit provinces in South Africa.

View Article and Find Full Text PDF

A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.

Clin Breast Cancer

December 2024

Medical Oncology and Palliative Care, Department of Medicine, Breast Cancer Disease Oriented Team, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792-3252.

Background: The SMILE study is a multi-institutional phase II clinical trial to determine the efficacy and safety of an antiprogestin, onapristone, in combination with fulvestrant as second-line therapy for patients with ER+, PgR+/-, HER2- metastatic breast cancer. This study was terminated early and herein, we report patient characteristics, and outcomes.

Methods: Eligibility criteria included disease progression on ≥2 lines of prior therapy, ECOG performance status ≤ 2, measurable disease per RECIST 1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!